...
首页> 外文期刊>International Journal of Pharmaceutics >pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect
【24h】

pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect

机译:pH敏感的顺铂与透明质酸的聚合物复合物表现出靶向肿瘤的作用并改善了体内抗肿瘤作用

获取原文
获取原文并翻译 | 示例

摘要

Cisplatin (CDDP) is widely used anticancer drug for various solid tumors including lung cancer. However, its indiscriminate distribution causes serious adverse effects and limits its therapeutic effect. In this study, by using hyaluronic acid (HA) we synthesized a complex of CDDP (HA-CDDP), by utilizing ionic interaction between Pt2+ of CDDP with carboxyl group of HA. The mean HA-CDDP particle size was 208.5 nm in PBS according to dynamic light scattering which was also confirmed by TEM, which could exert tumor-targeting property by enhanced permeability and retention (EPR) effect. The CDDP loading in this preparation was 13% (w/w), and release rate of free CDDP from the HA-CDDP complex at physiological pH (7.4) was similar to 20%/day. However, in acidic pH the release was much faster, i.e., similar to 95% of CDDP was released in 72 h at pH 5.5. Moreover, HA-CDDP showed a 2.5-fold higher tumor accumulation than free CDDP whereas no increase of distribution was found in most normal tissues. In addition, because HA receptor CD44 is overexpressed in many tumor cells, we also observed CD44-based endocytosis of HA-CDDP in mouse lung carcinoma LCC cells. These findings together suggest that HA-CDDP may show tumor-selective cytotoxicity by taking advantage of EPR effect, weak acidic environment of tumor tissues (e. g., pH 6 similar to 7), as well as CD44-based intracellular uptake. As expected, HA-CDDP exhibited much improved therapeutic effect than free CDDP in mouse LCC tumor model, whereas no apparent side effect was found. These findings may shed some light on the potential utility of HA for development of tumor-targeted polymeric CDDP drugs, which need further investigations. (C) 2015 Elsevier B.V. All rights reserved.
机译:顺铂(CDDP)被广泛用于包括肺癌在内的各种实体瘤的抗癌药物。然而,其不加选择的分布引起严重的副作用并限制了其治疗效果。在这项研究中,通过使用透明质酸(HA),我们利用CDDP的Pt2 +与HA的羧基之间的离子相互作用,合成了CDDP(HA-CDDP)的复合物。根据动态光散射,PBS中HA-CDDP的平均粒径为208.5 nm,这也得到了TEM的证实,这可以通过增强通透性和保留(EPR)效应发挥肿瘤靶向性。该制剂中的CDDP负载量为13%(w / w),并且在生理pH(7.4)下从HA-CDDP复合物释放的游离CDDP的释放速率类似于20%/天。然而,在酸性pH下,释放要快得多,即在pH 5.5下72小时内释放出类似于95%的CDDP。此外,HA-CDDP的肿瘤蓄积比游离CDDP高2.5倍,而在大多数正常组织中未发现分布增加。此外,由于HA受体CD44在许多肿瘤细胞中过表达,因此我们还在小鼠肺癌LCC细胞中观察到了基于CD44的HA-CDDP内吞作用。这些发现共同表明,HA-CDDP可通过利用EPR作用,肿瘤组织的弱酸性环境(例如,pH 6与7相似)以及基于CD44的细胞内摄取而显示出肿瘤选择性的细胞毒性。如所预期的,在小鼠LCC肿瘤模型中,HA-CDDP表现出比游离CDDP改善的治疗效果,而未发现明显的副作用。这些发现可能揭示了HA在开发靶向肿瘤的聚合CDDP药物方面的潜在用途,尚需进一步研究。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号